Literature DB >> 10771942

Recent advances in the treatment of congestive heart failure.

S C Chen1.   

Abstract

Treatment of heart failure should include correction of the underlying cause. These causes include large left to right shunts, obstructive lesions, arrhythmias, primary myocardial disease etc. The main pharmacological therapy includes inotropic agents, vasodilators and diuretics. Inotropic agents increase myocardial contractility and include digoxin, intravenous dopamine, dobutamine and isoproterenol. Vasodilators improve cardiac pump performance by decreasing the vascular resistance and/or increasing the venous capacitance. Commonly used vasodilator agents include angiotensin converting enzyme inhibitors (captopril, enalapril etc.), hydralazine, prazosin hydrochloride etc. Diuretics inhibit salt and water reabsorption promoting their excretion. Furosemide, thiazide diuretics, aldactone, are commonly used diuretics. Electrolyte and acid-base imbalance can occur on chronic diuretic therapy. Cardiac transplantation is considered for patients where all medical management has failed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10771942     DOI: 10.1007/bf02849687

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  9 in total

Review 1.  The management of chronic heart failure.

Authors:  J N Cohn
Journal:  N Engl J Med       Date:  1996-08-15       Impact factor: 91.245

Review 2.  Congestive heart failure in childhood and adolescence: recognition and management.

Authors:  M Artman; M D Parrish; T P Graham
Journal:  Am Heart J       Date:  1983-03       Impact factor: 4.749

3.  Guidelines for vasodilator therapy of congestive heart failure in infants and children.

Authors:  M Artman; T P Graham
Journal:  Am Heart J       Date:  1987-04       Impact factor: 4.749

Review 4.  Neuroendocrine changes in heart failure and their clinical relevance.

Authors:  W W Parmley
Journal:  Clin Cardiol       Date:  1995-08       Impact factor: 2.882

Review 5.  Pathophysiology and current therapy of congestive heart failure.

Authors:  W W Parmley
Journal:  J Am Coll Cardiol       Date:  1989-03-15       Impact factor: 24.094

Review 6.  Changing strategies in the management of heart failure.

Authors:  A M Katz
Journal:  J Am Coll Cardiol       Date:  1989-03-01       Impact factor: 24.094

Review 7.  Fundamental role of angiotensin-converting enzyme inhibitors in the management of congestive heart failure.

Authors:  L H Opie
Journal:  Am J Cardiol       Date:  1995-06-16       Impact factor: 2.778

8.  Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group.

Authors:  F Waagstein; M R Bristow; K Swedberg; F Camerini; M B Fowler; M A Silver; E M Gilbert; M R Johnson; F G Goss; A Hjalmarson
Journal:  Lancet       Date:  1993-12-11       Impact factor: 79.321

9.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.

Authors:  M Packer; M R Bristow; J N Cohn; W S Colucci; M B Fowler; E M Gilbert; N H Shusterman
Journal:  N Engl J Med       Date:  1996-05-23       Impact factor: 91.245

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.